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Abstract
Background: The therapeutic effect of adipose-derived mesenchymal stem cells (ADMSCs) on brain infarction area 
(BIA) and neurological status in a rat model of acute ischemic stroke (IS) was investigated.
Methods: Adult male Sprague-Dawley (SD) rats (n = 30) were divided into IS plus intra-venous 1 mL saline (at 0, 12 and 
24 h after IS induction) (control group) and IS plus intra-venous ADMSCs (2.0 × 106) (treated interval as controls) 
(treatment group) after occlusion of distal left internal carotid artery. The rats were sacrificed and brain tissues were 
harvested on day 21 after the procedure.
Results: The results showed that BIA was larger in control group than in treatment group (p < 0.001). The sensorimotor 
functional test (Corner test) identified a higher frequency of turning movement to left in control group than in 
treatment group (p < 0.05). mRNA expressions of Bax, caspase 3, interleukin (IL)-18, toll-like receptor-4 and 
plasminogen activator inhibitor-1 were higher, whereas Bcl-2 and IL-8/Gro were lower in control group than in 
treatment group (all p < 0.05). Western blot demonstrated a lower CXCR4 and stromal-cell derived factor-1 (SDF-1) in 
control group than in treatment group (all p < 0.01). Immunohistofluorescent staining showed lower expressions of 
CXCR4, SDF-1, von Willebran factor and doublecortin, whereas the number of apoptotic nuclei on TUNEL assay was 
higher in control group than in treatment group (all p < 0.001). Immunohistochemical staining showed that cellular 
proliferation and number of small vessels were lower but glial fibrillary acid protein was higher in control group than in 
treatment group (all p < 0.01).
Conclusions: ADMSC therapy significantly limited BIA and improved sensorimotor dysfunction after acute IS.
Background
Stroke, a growing epidemic, is the third most frequent
cause of mortality in industrialized countries [1-3].
Despite state-of-the-art therapy, clinical outcome after
stroke remains poor, with many patients left permanently
disabled [4]. Recently, thrombolytic therapy, a more
aggressive treatment strategy, has been reported to be
effective for some acute ischemic stroke (IS) patients
[5,6]. However, its liberal use is hampered by a lot of limi-
tations, including the need for early implementation
within the first hours after acute IS onset [5,7-9]. Of
importance is that thrombolytic therapy has been found
to have a relatively high incidence of serious hemorrhagic
complications [9,10]. Accordingly, finding a safe and
effective therapeutic alternative for patients following
acute IS, especially for those unsuitable for thrombolytic
therapy, is mandatory for physicians.
Cytotherapy has recently emerged as an attractive and
promising new therapeutic option for the treatment of
various ischemia-related disorders, i.e. cardiovascular
disease and stroke, in experimental studies [3,11-13].
Recent clinical trials have also proven its feasibility and
safety [3,11-14]. However, before envisaging cell-based
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therapy for improving ischemia-related neurologic dys-
function, some unresolved problems still need to be clari-
fied: 1) the ideal cell source for transplantation, 2) the
most appropriate route of cell administration, and, 3) the
best approach to achieve an appropriate and functional
integration of transplanted cells into the host tissue [3].
Interestingly, while stem cell therapy, including bone
marrow-derived mesenchymal stem cells [15-17], embry-
onic stem cells [14] and endothelial progenitor cells [18],
have been extensively investigated in the treatment of
stroke in experimental studies and, to a lesser extent, in
humankind, the use of adipose-derived mesenchymal
stem cells (ADMSCs) for the treatment of stroke has sel-
dom been discussed [19]. Compared with embryonic
stems cells and bone marrow-derived mesenchymal stem
cells, ADMSCs have the distinct advantages of being
abundant, easy to obtain with minimal invasiveness, and
readily cultured to a sufficient number for autologous
transplantation without ethical issue. Previous study has
also demonstrated a therapeutic superiority of ADMSCs
over bone marrow-derived mesenchymal stem cells in an
animal model of liver injury [20]. Therefore, we suggest
that cytotherapy using autologous ADMSC would be a
potential clinical approach to cardiovascular or cerebral
vascular disease. Accordingly, in the present study, we
tested the hypothesis that ADMSC therapy is safe and
effective in limiting the size of brain infarct and improv-
ing neurological function in a rat model of acute IS. We
further investigated whether intravenous administration
was an appropriate route for ADMSC implantation.
Methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at our
hospital and performed in accordance with the Guide for
the Care and Use of Laboratory Animals (NIH publica-
tion No. 85-23, National Academy Press, Washington,
DC, USA, revised 1996).
Isolation of Adipose-Derived Mesenchymal Stem Cells from 
Rat
The rats were anesthetized with inhalational isoflurane.
Adipose tissue surrounding the epididymis was carefully
dissected and excised. Then 200-300 μL of sterile saline
was added to every 0.5 g of tissue to prevent dehydration.
The tissue was cut into < 1 mm3 size pieces using a sharp,
sterile surgical scissors. Sterile saline (37°C) was added to
the homogenized adipose tissue in a ratio of 3:1 (saline:
adipose tissue), followed by the addition of stock collage-
nase solution to a final concentration of 0.5 Units/mL.
The tubes with the contents were placed and secured on a
Thermaline shaker and incubated with constant agitation
for 60 ± 15 min at 37°C. After 40 minutes of incubation,
the content was triturated with a 25 mL pipette for 2-3
min. The cells obtained were placed back to the rocker for
incubation. The contents of the flask were transferred to
50 mL tubes after digestion, followed by centrifugation at
600 g, for 5 minutes at room temperature. The fat layer
and saline supernatant from the tube were poured out
gently in one smooth motion or removed using vacuum
suction. The cell pellet thus obtained was resuspended in
40 mL saline and then centrifuged again at 600 g for 5
minutes at room temperature. After being resuspended
again in 5 mL saline, the cell suspension was filtered
through a 100 μm filter into a 50 mL conical tube to
which 2 mL of saline was added to rinse the remaining
cells through the filter. The flow-through was pipetted to
a 40 μm filter into a new 50 mL conical tube. The tubes
were centrifuged for a third time at 600 g for 5 minutes at
room temperature. The cells were resuspended in saline.
An aliquot of cell suspension was then removed for cell
culture in DMEM-low glucose medium contain 10% FBS
for two weeks. Flow cytometric analysis was performed
for identification of cellular characteristics after cell-
labeling with appropriate antibodies 30 minutes before
transplantation (Figure 1).
ADMSCs Labeling Before Autologous Transplantation
Thirty min prior to autologous transplantatting ADM-
SCs, CM-Dil (Vybrant™ Dil cell-labeling solution, Molec-
ular Probes, Inc.) (50 μg/ml) was added to the culture
medium. This highly lipophilic carbocyanine dye, which
has properties of low cytotoxicity and high resistance to
intercellular transfer, can be added directly to normal cul-
ture media to uniformly label suspended or attached cul-
ture cells for their visibility in a brain infarct area (BIA)
due to its distinctive fluorescence.
Animal Model of Acute Ischemic Stoke
Pathogen-free, adult male Sprague-Dawley (SD) rats,
weighing 300-350 g (Charles River Technology, Bio-
LASCO Taiwan Co., Ltd., Taiwan) were utilized in this
study. After adipose-derived mesenchymal stem cells
(ADMSCs) were cultured for two weeks, acute stroke was
induced in the animals. After exposure of the left com-
mon carotid artery (LCCA) through a transverse neck
incision, a small incision was made on the LCCA through
which a nylon filament (0.28 mm in diameter) was
advanced into the distal left internal carotid artery for
occlusion of left middle cerebral artery (LMCA) to induce
brain infarction of its supplying region. Three hours after
occlusion, the nylon filament was removed, followed by
closure of the muscle and skin in layers.
In Vivo Treatment Protocol
Ten healthy rats served as normal controls (group 1). The
rats with acute IS were divided into group 2 (acute IS
treated with 1 mL intravenous physiological saline at 0,Leu et al. Journal of Translational Medicine 2010, 8:63
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12 and 24 h after IS induction, n = 15) and group 3 [acute
IS plus intravenous ADMSCs (2.0 × 106 in 0.5 cc culture
medium for each time) given at 0, 12 and 24 h after IS
induction, n = 15). Five rats in groups 2 and 3 were uti-
lized for determining the brain infarct size. The senso-
rimotor functional test (Corner test) was performed by
blinded investigators for each rat on days 0, 1, 3, 7, 14 and
21 after acute IS induction as previously described [21].
Cellular Proliferation Test
To evaluate whether ADMSC treatment promotes cellu-
lar proliferation in the BIA, 5-bromodeoxyuridine (BrdU)
was intravenously given in all three groups of animals on
days 3, 5, 7, 9, and 12 after acute IS induction for labeling
the proliferating cells.
Specimen Collection
Rats in groups 1, 2, and 3 were euthanized on day 21 after
IS induction, and brain in each rat was rapidly removed
and immersed in cold saline. For immunohistofluores-
cence (IHF) study, the brain tissue was rinsed with PBS,
embedded in OCT compound (Tissue-Tek, Sakura, Neth-
erlands) and snap-frozen in liquid nitrogen before being
stored at -80°C. For immunohistochemical (IHC) stain-
ing, brain tissue was fixed in 4% formaldehyde and
embedded in paraffin.
Measurement of Brain Infarct Area
To evaluate the impact of ADMSC treatment on brain
infarction, coronal sections of the brain were obtained
from five extra animals in group 2 and group 3 (n = 5 for
each group) as 2 mm slices. Each cross section of brain
tissue was then stained with 2% 3,5-Triphenyl-2H-Tetra-
zolium Chloride (TTC)(Alfa Aesar) for BIA analysis.
Briefly, all brain sections were placed on a tray with a
scaled vertical bar to which a digital camera was attached.
The sections were photographed from directly above at a
fixed height. The images obtained were then analyzed
using Image Tool 3 (IT3) image analysis software (Uni-
versity of Texas, Health Science Center, San Antonio,
UTHSCSA; Image Tool for Windows, Version 3.0, USA).
Infarct area was observed as either whitish or pale yellow-
ish regions. Infarct region was further confirmed by
microscopic examination. The percentages of infarct area
were then obtained by dividing the area with total cross-
sectional area of the brain.
TUNEL Assay for Apoptotic Nuclei
For each rat, 6 sections of BIA were analyzed by an in situ
Cell Death Detection Kit, AP (Roche) according to the
manufacturer's guidelines. Three randomly chosen high-
power fields (HPFs) (×400) were observed for terminal
deoxynucleotidyl transferase-mediated 2'-deoxyuridine
5'-triphosphate nick-end labeling (TUNEL)-positive cells.
The mean number of apoptotic nuclei per HPF for each
animal was obtained by dividing the total number of cells
with 18.
IHC Staining for Cellular Proliferation and Glial Fibrillary 
Acid Protein (GFAP)
Paraffin sections (5 μm thick) with BIA were obtained
from each rat. To block the action of endogenous peroxi-
Figure 1 Flow cytometric analysis of rat adipose-derived mesenchymal stem cells (ADMSCs). Flow cytometry results of ADMSCs (the percent-
age shown in figure was mean value of n = 3) on day 14 after cell culturing showed the CD29 + and CD90+ cells were the highest population of stem 
cells. Spindle-shaped morphological feature of the stem cells were shown in the right lower corner (200×).Leu et al. Journal of Translational Medicine 2010, 8:63
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dase, the sections were initially incubated with 3% hydro-
gen peroxide for 15 minutes, and then further processed
using Beat Blocker Kit (invitrogen, #50-300) with immer-
sion in solutions A and B for 30 minutes and 10 minutes
at room temperature, respectively. Rabbit polyclonal anti-
body (1:500 dilution at 4°C overnight) against glial fibril-
lary acid protein (GFAP) (Dako) and monoclonal
antibody (1:200 dilution at 4°C overnight) against 5-
Bromo-2-DeoxyUridine (BrdU) (Sigma), were used as
primary antibodies. The anti-rabbit HRP (Zymed) (1:3
dilution at room temperature for 10 minutes) for GFAP
and anti-mouse HRP (Zymed) (1:3 dilution at room tem-
perature for 10 minutes) were used as secondary antibod-
ies, followed by application of SuperPicTure™ Polymer
Detection Kit (Zymed) for 10 minutes at room tempera-
ture. Finally, the sections were counterstained with hema-
toxylin. For negative control experiments, primary
antibodies were omitted.
Western Blot Analysis for CXCR4 and Stromal Cell-Derived 
Factor-1 in BIA
Equal amounts (60 μg) of protein extracts from BIA were
loaded and separated by SDS-PAGE using 12-13% acryl-
amide gradients. Following electrophoresis, the separated
proteins were transferred electrophoretically to a polyvi-
nylidene difluoride (PVDF) membrane (Amersham Bio-
sciences). Nonspecific proteins were blocked by
incubating the membrane in blocking buffer (5% nonfat
dry milk in T-TBS containing 0.05% Tween 20) overnight
for CXCR4 and one hour for stromal cell-derived factor
(SDF)-1, respectively. The membranes were incubated
with the indicated primary antibodies (CXCR4, 1:1000,
Abcam, Actin 1:10000, Chemicon; SDF-1, 1:1000, Cell
Signaling) for one hour at room temperature for CXCR4
and overnight at 4°C for SDF-1, respectively. Horseradish
peroxidase-conjugated anti-rabbit immunoglobulin IgG
(1:2000, Cell Signaling) was applied as the secondary anti-
body for one hour for CXCR4 and 45 minutes for SDF-1
at room temperature. The washing procedure was
repeated eight times within an hour, and immunoreactive
bands were visualized by enhanced chemiluminescence
(ECL) (Amersham Biosciences) and exposure to Biomax
L film (Kodak). For quantification, digitized ECL signals
were analyzed using Labwork UVP software.
Protocol for RNA Extraction
Lysis/binding buffer (High Pure RNA Tissue Kit, Roche,
Germany) 400 μL and an appropriate amount of frozen
brain tissue were added to a nuclease-free 1.5 mL micro-
centrifuge tube, followed by disruption and homogeniza-
tion of the tissue by using a rotor-stator homogenizer
(Roche).
For each isolation, 90 μL DNase incubation buffer was
pipetted into a sterile 1.5 mL reaction tube, 10 mL DNase
I working solution was then added, mixed and incubated
for 15 minutes at 25°C. Washing buffer I 500 μL was then
added to the upper reservoir of the filter tube, which was
then centrifuged for 15 seconds at 8,000 g. Washing buf-
fer II 300 μL was added to the upper reservoir of the filter
tube, which was centrifuged for 2 minutes full-speed at
approximately 13,000 g. Elution Buffer 100 μL was added
to the upper reservoir of the filter tube; the tube assembly
was then centrifuged for one minute at 8,000 g resulting
in eluted RNA in the microcentrifuge tube.
Real-Time Quantitative PCR Analysis
Real-time polymerase chain reaction (RT-PCR) was con-
ducted using LightCycler TaqMan Master (Roche, Ger-
many) in a single capillary tube according to the
manufacturer's guidelines for individual component con-
centrations. Forward and reverse primers were each
designed based on individual exons of the target gene
sequence to avoid amplifying genomic DNA.
During PCR, the probe was hybridized to its comple-
mentary single-strand DNA sequence within the PCR
target. As amplification occurred, the probe was
degraded due to the exonuclease activity of Taq DNA
polymerase, thereby separating the quencher from
reporter dye during extension. During the entire amplifi-
cation cycle, light emission increased exponentially. A
positive result was determined by identifying the thresh-
old cycle value at which reporter dye emission appeared
above background.
Immunohistofluorescence (IHF) analysis for CXCR4, SDF-1, 
Doublecortin, and von Willebrand Factor (vWF)
Serial cryosections (7 μm thick) with an average distance
of 5 μm apart were collected from the BIA. The sections
were fixed in acetone for 15 minutes at -20°C. For reduc-
ing the background, 200 μL of signal enhancer was uti-
lized for blocking non-specific signals at room
temperature for 30 minutes. IHF staining was performed
using primary antibody (rabbit polyclonal antibody 1:200
dilution, at 4°C, overnight) (Santa Cruz) for CXCR4, fol-
lowed by the addition of anti-rabbit Alexa Fluor 488 FITC
(Molecular Probes) secondary antibody (1:200 dilution at
room temperature for 30 minutes). Additionally, rabbit
polyclonal antibody (1:500 dilution at 4°C overnight)
(Santa Cruz) was used as primary antibody for SDF-1,
followed by the addition of anti-rabbit Alexa Fluor 594
Rodamin (Molecular Probes) secondary antibody (1:200
dilution at room temperature for 30 minutes). Moreover,
goat polyclonal antibody (1:50 dilution, at 4°C overnight)
(Santa Cruz) was used as primary antibody to recognize
doublecortin, followed by anti-goat Alexa Fluor 568
Rodamin (Molecular Probes) secondary antibody (1:200
dilution at room temperature for 30 minutes). Further-
more, rabbit polyclonal antibody (1:200 dilution at 4°CLeu et al. Journal of Translational Medicine 2010, 8:63
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overnight) (Chemicon) was used as primary antibody
against vWF, followed by anti-rabbit Alexa Fluor 488
FITC (Molecular Probes) secondary antibody (1:200 dilu-
tion at room temperature for 30 minutes). For negative
control experiments, the primary antibodies were omit-
ted. The sections were counterstained with 4', 6-Diamid-
ino-2-phenylindole (DAPI) (dilution 1/500) (Sigma) to
identify cellular nuclei that represented the cell number.
Oxidative Stress of BIA
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). The 2,4-dinitrophenyl-
hydrazine (DNPH) derivatization was carried out on 6 μg
of protein for 15 minutes according to manufacturer's
instructions. One-dimensional electrophoresis was car-
ried out on 12% SDS/polyacrylamide gel after DNPH
derivatization. Proteins were transferred to nitrocellulose
membranes which were then incubated in the primary
antibody solution (anti-DNP 1: 150) for 2 hours, followed
by incubation with second antibody solution (1:300) for
one hour at room temperature. The washing procedure
was repeated eight times within 40 minutes. Immunore-
active bands were visualized by enhanced chemilumines-
cence (ECL; Amersham Biosciences) which was then
exposed to Biomax L film (Kodak). For quantification,
ECL signals were digitized using Labwork software
(UVP). On each gel, a standard control was loaded.
Small Vessel Density in BIA
IHC staining of small blood vessels (i.e. diameters ≤ 15
mm) was performed with anti-α-SMA (1:400) as primary
antibody at room temperature for one hour, followed by
washing with PBS thrice. The anti-mouse HRP-conju-
gated secondary antibody was then added and incubated
for 10 minutes, followed by washing with PBS thrice.
Then 3,3' diaminobenzidine (DAB) (0.7 gm/tablet)
(Sigma) was added and incubated for one minute, fol-
lowed by washing with PBS thrice. Finally, following
hematoxylin treatment for one minute as a counter stain
for nuclei, the sections were washed twice. Three coronal
sections of the brain were analyzed in each rat. For quan-
tification, three randomly selected HPFs (200×) were ana-
lyzed in each section. The mean number of small vessel
per HPF for each animal was then determined by summa-
tion of all numbers divided by 9.
Statistical Analysis
Data were expressed as mean values (mean ± SD). The
significance of differences between two groups was evalu-
ated with t-test. The significance of differences among
three groups was evaluated using analysis of variance fol-
lowed by Bonferroni multiple-comparison post hoc test.
Statistical analyses were performed using SAS statistical
software for Windows version 8.2 (SAS institute, Cary,
NC). A probability value < 0.05 was considered statisti-
cally significant.
Results
ADMSC Therapy Limited Brain Infarct Size and Enhanced 
Recovery of Neurological Function (Figure 2)
TTC staining on day 21 after acute IS showed a mark-
edly larger BIA in IS animals without treatment (group 2)
compared with those having received ADMSC therapy
(group 3) (Figure 2A-C). Additionally, corner test demon-
strated a steady state of neurological functional impair-
ment on day 3 following acute IS in both group 2 and
group 3 (Figure 2D). On the other hand, progressive
improvement in neurological function after day 3 became
significant on day 14 in group 3 but not in group 2. More-
over, substantial improvement in group 3 was noted on
day 21 while persistent impairment of neurological func-
tion was observed in group 2 after acute IS.
By day 21 following ADMSCs implantation, immuno-
fluorescence stain (Figure 2E-F) identified that numerous
CM-Dil-stained ADMSCs were found to be present in
infarct area. This finding indicates that ADMSCs was
able to migrate (i.e. homing) to brain infarcted area after
venous injection.
Autologous Transplantation of ADMSCs Attenuated Anti-
Inflammatory Response, Apoptosis, and Oxidative Stress 
(Figures 3, 4 and 5)
On day 21 following acute IS induction, mRNA expres-
sions (Figure 3) of interleukin-18 (IL-18), toll-like recep-
tor (TLR)-4, and plasminogen activator inhibitor (PAI)-1
in BIA, indexes of inflammation, were significantly ele-
vated in group 2 compared with groups 1 and 3, and sig-
nificantly lower in group 1 than in group 3. These
findings indicate that ADMSC therapy attenuated
inflammatory reaction.
On day 21 following acute IS induction, Bcl-2 mRNA
expression, an anti-apoptotic index, was significantly
reduced in group 2 compared with groups 1 and 3, and
notably higher in group 1 than in group 3 (Figure 4A),
whereas mRNA expressions of Bax, an index of apoptosis,
was significantly elevated in group 2 compared with
groups 1 and 3, and notably lower in group 1 than in
group 3 (Figure 4B). Additionally, caspase 3 mRNA
expression, another indicator of apoptosis, was also
remarkably lower in group 1 than in groups 2 and, but it
did not differ between group 2 and group 3 (Figure 4C).
Furthermore, mRNA expression of IL-8/Gro, which has
been shown to regulate stem cells homing in response to
ischemic stress,21 was substantially higher in group 3 than
group 2 (Figure 4D). Moreover, TUNEL assay showed a
significantly reduced number of apoptotic nuclei in group
3 than in group 2 (Figure 4E-H).Leu et al. Journal of Translational Medicine 2010, 8:63
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Figure 2 Comparison of infarct area and sensorimotor function in rats with and without ADMSC treatment. (A & B) Identification of gross in-
farct area (blue arrows) with and without ADMSC treatment, respectively. (C) Significantly lower ratio of infarct area to total coronal section area in 
stroke + ADMSC group (group 3) compared with stroke group (group 2) (n = 5 per group). † vs. *, p < 0.001. (D) The results of Corner test on days 0, 
3, 7, 14, and 21 after acute IS, showing a steady state of neurological functional impairment on day 3 following acute IS in both group 2 and group 3. 
Significant improvement in neurological function noted only in group 3 compared with group 2 on day 14 and substantially improved on day 21 after 
acute IS. Significance of difference at respective time point: * p < 0.005, group 2 vs. group 3; † p < 0.002, group 2 vs. group 3. (E) and (F) Identification 
of CM-DiI-stained ADMSCs (yellow arrows) in brain infarct area of two rats from group 3. Scale bars in right lower corner represent 50 μm. Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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On day 21, Western blotting (Figure 5) demonstrated
that oxidative stress index in mitochondria was markedly
elevated in group 2 compared with that in groups 1 and 3,
and notably lower in group 1 than in group 3. These find-
ings indicate that ADMSC transplantation exerted both
anti-apoptotic and anti-inflammatory actions in the brain
after IS.
Autologous Transplantation of ADMSCs Enhanced In Vivo 
Angiogenesis and Neurogenesis (Figures 6, 7, 8, and 9)
IHC staining demonstrated that the number of cells
positive for CXCR4 (Figure 6A-D), a surface cell marker
of endothelial progenitor cells (EPCs), and SDF-1, a
chemokine for attraction of EPCs having CXCR4 recep-
tor (Figure 6E-H), was significantly higher in group 3
than in group 2, suggesting an enhancement of circulat-
ing EPC homing to ischemic area of the brain following
ADMSC treatment. Consistently, Western blot analysis
revealed significantly higher protein expressions of
CXCR4 (Figure 6I) and SDF-1 (Figure 6J) in group 3 than
in group 2.
The expression of doublecortin, an indication of
migrating neuroblasts, was remarkably upregulated in
group 3 compared with group 2 (Figure 7A-D). Addition-
ally, IHC staining showed that the expression of vWF, a
marker of endothelial cells of cerebral blood vessels, was
significantly increased in group 3 than in group 2 (Figure
7E-H). Moreover, IHC staining also revealed a notably
increased number of BrdU-positive cells (Figure 8A-D) in
group 3 than in group 2, implying an increased cellular
differentiation and proliferation after ADMSC treatment.
Furthermore, the number of arterioles (≤ 15 μm in diam-
eter) in BIA was substantially lower in group 2 than in
groups 1 and 3 on IHC staining (Figure 9A-D). All of
these findings indicate an ADMSC-induced enhance-
ment in neurogenesis and vasculogenesis after acute IS.
Autologous ADMSC Transplantation Reduced Glial 
Fibrillary Acid Protein (GFAP) Expression in Infarcted Brain 
(Figure 10)
IHC staining showed that GFAP expression, the princi-
pal intermediate filament of mature astrocytes, was nota-
bly lower in group 3 than in group 2 (Figure 10A to 10D),
suggesting reduced IS-induced gliosis after ADMSC
treatment.
Double Stains of CM-Dil and DAPI, and CM-Dil and vWF 
(Figure 11)
To determine whether transplanted ADMSCs were
really homing to the BIA, double stain of CM -Dil and
DAPI was done. As expected, the CM-Dil and DAPI-pos-
itively stained cells were found to engraft into the BIA
(Figure 11A). Additionally, to evaluate whether the
implanted ADMSCs were able differentiation into
endothelial cell phenotype, double stain of CM-Dil and
vWF was performed. The results showed that some of the
CM-Dil and vWF-positively cells were found to integrate
into small vessels (Figure 11C-D). This finding implicates
that some of ADMSCs might differentiate into endothe-
lial cells.
Discussion
This study, which investigated whether ADMSC therapy
limited brain infarct size and promoted neurological
recovery in a rat model of acute IS, produces several
important findings. First, ADMSC therapy enhanced
angiogenesis/vasculogenesis and neurogenesis. Second,
Figure 3 mRNA expressions of inflammatory mediators in brain 
infarct area. Significantly higher mRNA expressions of (A) interleukin 
(IL)-18, (B) toll-like receptor (TLR)-4, and (C) plasminogen activator in-
hibitor (PAI)-1 in group 2 than in group 3 and normal controls (group 
1), and notably higher in group 3 than in group 1. (n = 10 per group) * 
vs. †, p < 0.001; * vs. ‡, p < 0.01; † vs. ‡, p < 0.04.Leu et al. Journal of Translational Medicine 2010, 8:63
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Figure 4 mRNA expressions of apoptosis-related genes and number of apoptotic cells in brain infarct area. (A) Bcl-2 mRNA expression was 
significantly higher in groups 1 and 3 than in group 2 and notably higher in group 1 than in group 3. (B) Bax mRNA expression was notably higher in 
group 2 than in groups 1 and 3 and significantly higher in group 3 than in group 1. (C) Caspase 3 mRNA significantly higher in groups 2 and 3 than in 
group 1, but it did not differ between group 2 and group 3. (D) IL-8/Gro mRNA expression was remarkably higher in groups 2 and 3 than in group 1 
and notably higher in group 3 than in group 2. * vs. †, p < 0.05; * vs. ‡, p < 0.05; † vs. ‡, p < 0.05. The number of apoptotic nuclei (H)) (400×) significantly 
higher in group 2 (F) than in groups 1 (G) and 3 (E), and notably higher in group 3 than in group 1. (n = 10 per group) * vs. † vs. ‡, p < 0.001. Scale bar 
in right lower corner represent 20 μm.Leu et al. Journal of Translational Medicine 2010, 8:63
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ADMSC therapy attenuated inflammatory reaction and
apoptosis in BIA. Third, ADMSC therapy significantly
limited brain infarct size and improved neurological out-
come.
Limitation and Prospect of Stem Cell Therapy for Patients 
after Acute Ischemic Stroke
The preliminary results of stem cell therapy appear to be
promising for stroke patients in restoring sensorimotor
functions [3,4,14,18,22,23]. The validity of its clinical
applicability, however, depends on tangible evidence on
its safety and effectiveness as well as a thorough under-
standing of the underlying mechanism of actions. The use
of an animal model of acute IS, therefore, is imperative to
investigate the short and long-term effects of such a novel
treatment strategy [23]. Currently, several candidates of
stem cells, including embryonic stem cell, neuron stem
cells, bone marrow-derived mesenchymal stem cell, and
peripheral blood-derived stem cells have been frequently
investigated for their feasibility and safety in the treat-
ment of stroke in both clinical observational studies and
animal models [3,4,14,18,22-24]. However, the applica-
tion of these stem cells for stroke patients is commonly
hampered by a lot of limitations, including ethical prob-
lems with using embryonic stem cells, difficulties in dif-
ferentiation, lineage restriction and identification as well
as limitation of number and functional integrity in neu-
ron stem cells, peripheral blood-revived stem cell, and
bone marrow-derived stem cells [3,22-24]. One impor-
tant finding in the present study was that the Dil dye-
label ADMSCs were identified on day 21 after acute IS
induction. Additionally, transplantation of ADMSCs
facilitated recovery of forelimb function in the Corner
test. These findings, in addition to supporting our origi-
nal hypothesis, may provide one of ideal cell source, i.e.
ADMSCs, for transplantation. The administration of
ADMSCs through the systemic venous route has also
been validated in this study. Our results, therefore, offer a
potential clinical avenue for the future use of ADMSCs in
IS patients.
ADMSC Therapy Enhances Angiogenesis and Neurogenesis
SDF-1α is an endothelial progenitor cell chemokine par-
ticipating in the mobilization, incorporation, homing,
survival, proliferation, and differentiation of stem cells
[18,25]. Recently, SDF-1α and its receptor CXCR4 are
proven crucial in bone marrow retention of hematopoi-
etic stem cells, angiogenesis, and recruitment of EPCs
into ischemic tissue [18,25-29]. Another important find-
ing in the current study was that both Western blot and
IHC staining demonstrated that both CXCR4 and SFD-1
expressions were substantially increased in animals with
acute IS as compared with the normal controls. These
findings, therefore, are comparable to those of previous
studies [25-29]. Importantly, CXCR4 and SDF-1 in BIA
were found to be markedly increased after ADMSC treat-
ment. A recent study has recently demonstrated that
administration of SDF-1α to an animal model of critical
limb ischemia enhances the concentrations of EPCs
within the ischemic tissue and augments tissue reperfu-
sion [28]. Taking this finding [28] into consideration, our
results suggest that the enhancement of the number of
CXCR4-positive cells in BIA by administration of ADM-
SCs may be partially through reinforcing SDF-1α
chemokine expression in the BIA.
Beside the findings of upregulated expressions of
CXCR4 and SDF-1α in BIA, ADMSC therapy also mark-
edly increased the cellular expression of vWF that is a
marker of endothelial cells. Importantly, ADMSC therapy
also increased the number of small vessels in BIA. Taken
together, the improved neurological function and
reduced BIA in the present study could be explained, at
least in part, by the impact of angiogenesis.
As expected, the current study revealed that adminis-
tration of ADMSCs significantly increased the number of
doublecortin-positive cells in BIA. Additionally, BrdU
uptake in BIA, an index of cellular differentiation and
proliferation, was substantially promoted following
ADMSC treatment. Accordingly, the results of the pres-
Figure 5 Oxidative index in brain infarct area. Western blotting 
showing notably increased oxidative index, protein carbonyls, in BIA of 
group 2 compared with groups 1 and 3 on day 21 following acute IS 
(upper panel), with quantification results of each group (n = 10) shown 
(lower panel). * vs. † vs. ‡, p < 0.009.Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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Figure 6 Cellular expressions of CXCR4 and stromal derived factor (SDF)-1 in brain infarction area. Immunohistofluorescence (IHF) staining 
(400×) showing substantially lower number of CXCR4-positive cells (red arrows) in group 1 (A) than in groups 2 (B) and 3 (C), and remarkably lower 
in group 2 than in group 3; (D) indicated quantification results of each group (n = 10). ‡ vs. † vs. *, p < 0.001. IHF staining (400×) also demonstrating 
significantly lower number of SDF-1 positive cells (yellow arrows) in group 1 (E) than in groups 2 (F) and 3 (G), and notably lower in group 2 than in 
group 3. (H) indicated quantification results of each group (n = 10). ‡ vs. † vs. *, p < 0.001. Western blotting showing markedly lower CXCR4 (I) and 
SDF-1 (J) protein expressions in group 1 than in groups 2 and 3, and notably lower in group 2 than in group 3. n = 10 per group. Scale bars in right 
lower corner represent 50 μm. * vs. † vs. ‡, p < 0.01.Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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Figure 7 The distribution of neuroblasts and endothelial cells in brain infarction area. Results of IHF staining (D) (400×) showing significantly 
lower number of doublecortin-positive cells (yellow arrows) in group 1 (A) than in groups 2 (B) and 3 (C), and significantly lower in group 2 than in 
group 3. IHF staining (H) (400×) demonstrating significantly lower number of von Willibrand factor (vWF)-positive cells (yellow arrows) in group 1 (E) 
than in groups 2 (F) and 3 (G), and notably lower in group 2 than in group 3 (H). n = 10 in each study group. Scale bars in right lower corner represent 
20 μm. * vs. † vs. ‡, p < 0.001.Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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ent study suggest that ADMSC therapy enhances both
neurogenesis and vasculogenesis. These findings could be
another explanation for the reduction in BIA and
improvement in neurological function.
ADMSC Therapy Attenuates Inflammatory Response, 
Oxidative Stress, and Apoptosis
In the present study, the mRNA expressions of IL-18,
TLR-4, and PAI-1 were markedly upregulated in rats after
acute IS. In addition, the mRNA expressions of Bax and
caspase 3 were remarkably increased, whereas mRNA
expression of Bcl-2 was notably reduced in rats after
acute IS. Furthermore, TUNEL assay and IHC staining
demonstrated markedly increased number of apoptotic
nuclei and GFAP-positive cells, respectively, after acute
IS. Moreover, Western blot showed remarkably upregu-
lated oxidative stress in rats after acute IS. Surprisingly,
these biomarkers were significantly reversed by ADMSC
therapy. Recently, Thum et al. proposed that stem cell
therapy modulates immune reactivity by down-regulating
innate and adaptive immunity [30]. Accordingly, our find-
ings not only reinforce this hypothesis [30], but also
account for the improvement in neurological outcome
after ADMSC treatment in rats following acute IS.
ADMSC Therapy Improves Neurological Function-
Mechanisms of Uncertainty
Although the role of mesenchymal stem cell therapy in
improving ischemia-related organ dysfunction have been
well established [12-14,31-33], the exact mechanism
remains unclear [12,32]. The proposed mechanisms,
including angiogenesis [12,34] cytokine effects [12,15,34],
effect of paracrine mediators [12,15,32,33], neurogenesis
[14,16-18], or a stem-cell homing effect [16,35], underly-
ing improved ischemia-related organ dysfunction follow-
Figure 8 The distribution of proliferative cells in brain infarction area. Immunohistochemical (IHC) staining (D) (400×) showing markedly lower 
number of 5-bromodeoxyuridine (BrdU)-positive cells (red arrows) in groups 1 (A) and 2 (B) than in group 3 (C). No difference of BrdU-positive cells 
between groups 1 and 2. n = 10 in each group. Scale bars in right lower corner represent 50 μm. * vs. †, p = 0.096; * vs. ‡, p < 0.0001; † vs. ‡, p < 0.0001.Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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Figure 9 The number of arterioles in brain infarction area. Small vessels (diameters ≤ 15 mm) (red arrows) quantification for each group (n = 10) 
on 21 day following acute IS (D). Identification of blood vessel distribution in BIA using α-SMA immunohistochemical staining, showing notably higher 
small vessel number in groups 1 (A) and 3 (C) than in group 2 (B) (200×), and similar between groups 3 and 1. Scale bars in right lower corner represent 
50 μm. † vs. *, p < 0.0001.
Figure 10 The number of GFAP-positive cells in brain infarct area. IHC staining (D) (200×) showing significantly higher number of glial fibrillary 
acid protein (GFAP)-positive cells (red arrows) in group 2 (B) than in groups 1 (A) and 3 (C), and no difference between groups 1 and 3. n = 10 per 
group. Scale bars in right lower corner represent 50 μm. * vs. †, p < 0.0001.Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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ing mesenchymal stem cell therapy have been extensively
debated.
In the current study, although only a relatively lower
percentage of implanted cells were positive for neuron
surface makers, including nestin and microtubule-associ-
ated protein 2 (MAP-2), on flow cytometric analysis fol-
l o w i n g  1 4  d a y s  o f  c u l t u r i n g ,  b o t h  p a t h o l o g i c a l  f i n d i n g
(TTC staining) and corner test demonstrated that intra-
venous administration of ADMSCs into ischemic stroke
animals significantly reduced brain IA and remarkably
improved the recovery of neurological function in this
study compared to animals with ischemic stroke treated
by saline injection alone. Accordingly, rather than sup-
porting a crucial role of direct cellular participation in
limiting brain infarct size and improving neurological
function, our findings suggest the existence of other
unproved confounders.
The present study has limitations. First, although the
mechanisms underlying the therapeutic potential of
ADMSC in attenuating BIA and enhancing sensorimotor
functional recovery have been carefully elucidated, the
precise mechanistic basis of ADMSC treatment for acute
IS may be more complex. The proposed mechanisms of
potential impacts of ADMSC implantation on improving
sensorimotor dysfunction in the rat have been summa-
rized in Figure 12. Second, although the short-term out-
come was impressive, this current study does not provide
the information for how long the therapeutic effect will
be maintained.
In conclusion, ADMSC therapy limited brain infarct
size and improved neurological function in rats after
acute IS through enhancement of angiogenesis/vasculo-
genesis and neurogenesis as well as its anti-inflammatory
and anti-apoptotic effects.
Figure 11 Identification of ADMSCs in brain infarct area and differentiation into endothelial-cell phenotype. The IHF imaging (A) (400×) re-
sults showing double stains of CM-Dil and DAPI-positive cells (white arrows) in the brain infarct area. The number of these double stained cells ex-
pressed as percentage (B). The merge results of IHF (400×) showing the double stain of CM-Dil and vWF-positive cells (C) (white arrows) and bright 
field (D) image (800×) further confirmed the presence of these cells (white arrows). Scale bars in right lower corner represent 20 μm in (A) and (D) and 
10 μm in (D).Leu et al. Journal of Translational Medicine 2010, 8:63
http://www.translational-medicine.com/content/8/1/63
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